Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;12(2):80-82.
doi: 10.15420/ecr.2017:12:1.

Hypertrophic Cardiomyopathy in Athletes

Affiliations
Review

Hypertrophic Cardiomyopathy in Athletes

Aneil Malhotra et al. Eur Cardiol. 2017 Dec.

Abstract

Sudden cardiac death (SCD) in a young person is a rare but tragic occurrence. The impact is widespread, particularly in the modern era of media coverage and visibility of social media. Hypertrophic cardiomyopathy (HCM) is reported historically as the most common cause of SCD in athletes younger than 35 years of age. A diagnosis of HCM may be challenging in athletes as pathological hypertrophy of the left ventricle may also mimic physiological left ventricular hypertrophy (LVH) in response to exercise. Differentiation of physiological LVH from HCM requires an array of clinical tools that rely on detecting subtle features of disease in a supposedly healthy person who represents the segment of society with the highest functional capacity. Most studies are based on comparisons of clinical tests between healthy unaffected athletes and sedentary individuals with HCM. However, data are emerging that report the clinical features of athletes with HCM. This article focuses on studies that help shed further light to aid the clinical differentiation of physiological LVH from HCM. This distinction is particularly important in a young person: a diagnosis of HCM has significant ramifications on participation in competitive sport, yet an erroneous diagnosis of physiological adaptation in a young athlete with HCM may subject them to an increased risk of SCD.

Keywords: Athlete’s heart; hypertrophic cardiomyopathy; left ventricular hypertrophy; sudden cardiac death.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The author has no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:. Characteristics of Athletes with Hypertrophic Cardiomyopathy Compared to Sedentary Patients with Hypertrophic Cardiomyopathy that Highlight the Need to Utilize an Array of Clinical Tools Available to the Clinician

References

    1. Maron B. Structural features of the athlete heart as defined by echocardiography. JACC. 1986;7:190–203. - PubMed
    1. Pelliccia A, Maron BJ, Spataro A et al. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med. 1991;324:295–301. doi: 10.1056/NEJM199101313240504. - DOI - PubMed
    1. Basavarajaiah S, Wilson M, Whyte G et al. Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening. J Am Coll Cardiol. 2008;51:1033–9. doi: 10.1016/j.jacc.2007.10.055. - DOI - PubMed
    1. Maron BJ, Doerer JJ, Haas TS et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation. 2009;199:1085–92. doi: 10.1161/CIRCULATIONAHA.108.804617. - DOI - PubMed
    1. Harmon KG, Asif IM, Klossner D, Drezner JA. Incidence of sudden cardiac death in National Collegiate Athletic Association athletes. Circulation. 2011;123:1594–1600. doi: 10.1161/CIRCULATIONAHA.110.004622. - DOI - PubMed

LinkOut - more resources